Bank of New York Mellon Corp Makes New $17.55 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Bank of New York Mellon purchased 377,402 shares of Supernus Pharmaceuticals in the second quarter, valued at approximately $17.55 million and representing a 0.65% stake.
• Analyst sentiment is broadly positive but mixed: Supernus has an overall “Moderate Buy” rating and an average price target of $62.83, compared with a recent share price of $44.21.
• The company’s latest quarterly revenue rose 32.4% year over year to $219.06 million, exceeding estimates, but it reported an adjusted loss of $1.01 per share versus expectations for earnings of $0.42.

Bank of New York Mellon Corp purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 377,402 shares of the specialty pharmaceutical company's stock, valued at approximately $17,553,000. Bank of New York Mellon Corp owned 0.65% of Supernus Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Rockefeller Capital Management L.P. boosted its stake in Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company's stock valued at $42,000 after buying an additional 660 shares during the period. EverSource Wealth Advisors LLC bought a new position in shares of Supernus Pharmaceuticals in the second quarter worth approximately $51,000. Hantz Financial Services Inc. increased its position in shares of Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company's stock worth $54,000 after purchasing an additional 458 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Supernus Pharmaceuticals in the second quarter valued at approximately $55,000. Finally, Osaic Holdings Inc. grew its stake in Supernus Pharmaceuticals by 211.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company's stock worth $63,000 after buying an additional 1,328 shares in the last quarter.

Wall Street Analyst Weigh In

SUPN has been the subject of several research reports. Weiss Ratings reiterated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Cantor Fitzgerald increased their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 6th. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $62.83.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $44.21 on Tuesday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $42.45 and a fifty-two week high of $59.68. The firm's 50-day simple moving average is $46.81 and its two-hundred day simple moving average is $48.59. The stock has a market cap of $2.57 billion, a PE ratio of -23.03, a price-to-earnings-growth ratio of 0.81 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.42 by ($1.43). The company had revenue of $219.06 million for the quarter, compared to analysts' expectations of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm's quarterly revenue was up 32.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.40 EPS. Equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source